Oak Hill Bio In The Press

Making Headlines in Advancing Rare Disease Therapies.

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome

April 15, 2025

Oak Hill Bio and Chiesi Group Announce First European Patient Enrolled in the Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants

November 4, 2024

Oak Hill Bio Announces Promotion of Josh Distler to Chief Executive Officer and Additional Updates to Executive Team and Board

October 7, 2024

Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia in Premature Infants

May 17, 2024

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

January 9, 2024

Oak Hill Bio Joins C-Path’s International Neonatal Consortium

August 24, 2022

Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference

July 2, 2022

Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium

May 27, 2022

Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology

May 25, 2022

2022 RBC Capital Markets Global Healthcare Conference

May 18, 2022

Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference

May 12, 2022

Oak Hill Bio Launches with Pipeline and Senior Leadership from Takeda

February 1, 2022